Why is hepatic impairment considered in PK? how does it affect hepatic clearance?

• A. Reduces hepatic clearance depending on mechanism; often increases AUC and t1/2.
• B. It increases hepatic clearance.
• C. It has no effect on CLint or hepatic blood flow.
• D. It only decreases fu.

Answer: (A)

Hepatic clearance depends on three main factors: intrinsic metabolic capacity of the liver (enzyme activity), hepatic blood flow, and how much drug is unbound in the blood (fu). In hepatic impairment, the liver’s ability to metabolize drugs is reduced because enzyme activity and sometimes the amount of functioning liver tissue are diminished, and blood flow to the liver can also be decreased. Protein binding can also change with liver disease, which alters the unbound fraction.

For drugs with low extraction, hepatic clearance is roughly proportional to fu × CLint. If impairment lowers CLint and can alter fu, the clearance decreases, leading to higher systemic exposure (increased AUC) and a longer half-life. For high-extraction drugs, hepatic clearance is more limited by hepatic blood flow; when liver disease reduces hepatic blood flow, clearance falls as well, again elevating AUC and prolonging t1/2.

So hepatic impairment typically reduces hepatic clearance, with the exact effect depending on whether the drug is a low- or high-extraction compound, and this reduction commonly results in higher AUC and longer t1/2. The other statements don’t fit because impairment often decreases clearance rather than increasing it, it does affect CLint and/or blood flow, and changes in fu are not the sole or guaranteed effect.